Gilead Sciences, Inc.

Calithera Biosciences, Inc.

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Bindu Goyal

Richard L Mackman

Dustin S Siegel

Gregory F Chin

Michael O Clarke

Eric Brian Sjogren

Jim W Li

Hai Yang

Lijing Chen

Timothy Friend Stanton

Guy Laidig

Hon Chung Hui

Petr Jansa

Michael R Mish

Byoung-Kwon Chun

Mark J Bartlett

Jennifer Leigh Cosman

Deeba Ensan

Stephen Ho

Bernd Buettelmann

Scott D Schroeder

Wylie Solang Palmer

Nathan D Shapiro

Daniel H Byun

Doris T Tang

Kyle C Tamshen

Jim Li

The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.

Antiviral compounds

The present disclosure provides pyrimidine dione compounds of Formula I

CD73 compounds

The present disclosure describes 4'-fluoromethyl nucleosides for treating viral infections, including Dengue.

Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.

Heterocyclic glutaminase inhibitors

Heterocyclic inhibitors of glutaminase

Compounds of formula (I) modulate JNK wherein Xand Xare each simultaneously N or CH; Xis CH&#x2014;ROr N&#x2014;SOR, where R is lower alkyl; Ris aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; Ris (II), where Ris H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof. 

JNK modulators

Growing community of inventors

Fremont, CA, United States of America

Bindu Goyal